Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.

Bcr-348r_msds

SAFETY DATA SHEET
Based on Directive 2001/58/EC of the Commission of the European Communities
PROGESTERONE
Identification of the substance/preparation and of the company/undertaking
1.1 Identification of the substance or preparation:
Synonyms:
: 57-83-0
Reference number :
EC index No.
NFPA code
: 0-1-0(*)
Molecular weight
Formula :
1.2 Use of the substance or the preparation:
Certified reference material for laboratory use only 1.3 Company/undertaking identification:
Institute for Reference Materials and Measurements 1.4 Telephone number for emergency:
p/a Militair Hospitaal Koningin Astrid, Bruynstraat 1, B-1120 Brussel Composition/information on ingredients
Hazardous ingredients
Conc. in Hazard
EINECS/ELINCS No.
(R-phrases)
(1) For R-phrases in full: see heading 16 3. Hazards
identification
- Limited evidence of a carcinogenic effect First aid measures
4.1 Eye contact:
- Consult a doctor/medical service if irritation persists 4.2 Skin contact:
- Consult a doctor/medical service if irritation persists 4.3 After inhalation:
- Consult a doctor/medical service if breathing problems develop - Unconscious: maintain adequate airway and respiration 4.4 After ingestion:
- Consult a doctor/medical service if you feel unwell - Never give water to an unconscious person : 11-2005
: Brandweerinformatiecentrum voor Gevaarlijke Stoffen vzw (BIG) Technische Schoolstraat 43 A, B-2440 Geel PROGESTERONE
5. Fire-fighting
measures
5.1 Suitable extinguishing media:
5.2 Unsuitable extinguishing media:
5.3 Special exposure hazards:
5.4 Instructions:
- No specific firefighting instructions required 5.5 Special protective equipment for firefighters:
- Heat/fire exposure: compressed air/oxygen apparatus - Protective clothing for exposure to chemicals Accidental release measures
6.1 Personal protection/precautions:
6.2 Environmental precautions:
6.3 Methods for cleaning up:
- Scoop solid spill into closing containers - Clean contaminated surfaces with an excess of water - Wash clothing and equipment after handling Handling and storage
7.1 Handling:
7.2 Storage:
- Keep away from: heat sources, ignition sources, oxidizing agents temperature
Quantity
Materials for packaging
7.3 Specific uses:
- See information supplied by the manufacturer : 11-2005
PROGESTERONE
Exposure controls/Personal protection
8.1 Exposure limit values:
TLV-STEL
TLV-Ceiling
OES-LTEL
OES-STEL
MEL-LTEL
MEL-STEL
MAC-TGG 8 h
: not listed
MAC-TGG 15 min.
: not listed
MAC-Ceiling
Momentary
Sampling
methods:
8.2 Exposure controls:
8.2.1 Occupational exposure controls:
- Measure the concentration in the air regularly 8.2.2 Environmental exposure controls: see heading 13
8.3 Personal protection:
8.3.1 respiratory
protection:
- Dust production: dust mask with filter type P2 8.3.2 hand
protection:
8.3.3 eye
protection:
- In case of dust production: protective goggles 8.3.4 skin
protection:
: 11-2005
PROGESTERONE
Physical and chemical properties
9.1 General information:
9.2 Important health, safety and environmental information:
vol% ( °C)
0.00088 g/100 ml
9.3 Other information:
10. Stability and reactivity
10.1 Conditions to avoid/reactivity:
10.2 Materials to avoid:
- Keep away from: heat sources, ignition sources, oxidizing agents 10.3 Hazardous decomposition products:
: 11-2005
PROGESTERONE
11. Toxicological
information
11.1 Acute toxicity:
LD50 oral rat
LD50 dermal rat
: N.D. mg/kg
LD50 dermal rabbit
: N.D. mg/kg
LC50 inhalation rat : N.D. mg/l/4
LC50 inhalation rat : N.D.
11.2 Chronic toxicity:
EC carc. cat.
EC muta. cat.
: not listed
EC repr. cat.
: not listed
Carcinogenicity (TLV) : not listed
Carcinogenicity (MAC) : not listed
Carcinogenicity (VME) : not listed
Carcinogenicity (GWBB) : not listed
Carcinogenicity (MAK) : not listed
Mutagenicity (MAK)
: not listed
Teratogenicity (MAK)
IARC classification

11.3 Routes of exposure:
11.4 Acute effects/symptoms:
AFTER INGESTION
- Change in the haemogramme/blood composition AFTER SKIN CONTACT
11.5 Chronic effects:
- No certainty about human carcinogenic properties - Not listed in mutagenicity class (EC,MAK) - Not classified as toxic to reproduction (EC) : 11-2005
PROGESTERONE
12. Ecological
information
12.1 Ecotoxicity:

12.2 Mobility:
Volatile organic compounds (VOC): 0%
For other physicochemical properties see heading 9 12.3 Persistence and degradability:
- biodegradation BOD5 :
: T ½: N.D.
12.4 Bioaccumulative potential:
12.5 Other adverse effects:
- Effect on the ozone layer
- Greenhouse effect
- Effect on waste water purification
13. Disposal
considerations
13.1 Provisions relating to waste:
- Waste material code (91/689/EEC, Council Decision 2001/118/EC, O.J. L47 of 16/2/2001): 16 05 06* (laboratory chemicals, consisting of or containing dangerous substances, including mixtures of laboratory chemicals) 13.2 Disposal methods:
- Remove to an authorized incinerator equipped with an afterburner and a flue 13.3 Packaging/Container:
- Waste material code packaging (91/689/EEC, Council Decision 2001/118/EC, O.J. L47 of 16/2/2001): 15 01 10* (packaging containing residues of or : 11-2005
PROGESTERONE
14. Transport
information
14.1 Classification of the substance in compliance with UN Recommendations
PROPER SHIPPING NAME
14.2 ADR (transport by road)
: NOT SUBJECT
DANGER LABEL TANKS
DANGER LABEL PACKAGES
14.3 RID (transport by rail)
: NOT SUBJECT
DANGER LABEL TANKS
DANGER LABEL PACKAGES
14.4 ADNR (transport by inland waterways)
: NOT SUBJECT
DANGER LABEL TANKS
DANGER LABEL PACKAGES
14.5 IMDG (maritime transport)
: NOT SUBJECT
POLLUTANT
14.6 ICAO (air transport)
: NOT SUBJECT
PACKING INSTRUCTIONS PASSENGER AIRCRAFT
PACKING INSTRUCTIONS CARGO AIRCRAFT
14.7 Special precautions in connection with
: not restricted for any mode of
transport
15. Regulatory
information
Not listed in Annex I of directive 67/548/EEC et sequens. Labelling established on the basis of the available data. (1) Limited evidence of a carcinogenic effect (1) Wear suitable protective clothing and gloves (1) (If swallowed, seek medical advice immediately and show (1) Does not need to be mentioned on packages < 125 ml : 11-2005
PROGESTERONE
16. Other
information
The information provided on this MSDS is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered as a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other material or in any process, unless specified in the text. Exposure limits:
Occupational Exposure Standards - United Kingdom 2003 Maximum Exposure Limits - United Kingdom 2003 Maximale Arbeitsplatzkonzentrationen - Germany 2002 Technische Richtkonzentrationen - Germany 2002 Maximale aanvaarde concentratie - The Netherlands 2004 Valeurs limites de Moyenne d’Exposition - France 1999 Valeurs limites d’Exposition à court terme - France 1999 Grenswaarde beroepsmatige blootstelling - Belgium 2002 Grenswaarde kortstondige blootstelling - Belgium 2002 : Indicative occupational exposure limit values - directive 2000/39/EC Inhalable fraction = T: Total dust = E: Einatembarer Aerosolanteil
Respirable fraction = A: Alveolengängiger Aerosolanteil/Alveolar dust
Chronic toxicity:
List of the carcinogenic substances and processes - The Netherlands 2005 Full text of any R-phrases referred to under heading 2:
: Limited evidence of a carcinogenic effect : 11-2005

Source: https://irmm.jrc.ec.europa.eu/html/reference_materials_catalogue/catalogue/attachements/BCR-348R_msds.pdf

schulterspezialist-muenchen.de

Publikationsliste von PD Dr. med. habil. Mark Tauber 1. Tauber M, Resch H, Forstner R, Raffl M, Schauer JReasons for failure after surgical repair of anterior shoulder instability. J Shoulder Elbow Surg. 2004 May-Jun;13(3):279-85. Sigmoid perforation after medial migration of lag screw in gamma nailing. Arch Orthop Trauma Surg. 2006 Mar;126(2):118-22. 3. Tauber M, Ritter E, Kelly B, Hitzl W,

Family caregiving statistics

FAMILY CAREGIVING STATISTICS Published by: More than one quarter (26.6%) of the adult population has provided care for a chronically ill,disabled or aged family member or friend during the past year. Based on current census data,that translates into more than 50 million people. Source: National Family Caregivers Association (NFCA) RandomSample Survey of 1000 Adults, Funded by CareThere.co

Copyright © 2010-2014 Medicament Inoculation Pdf